Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 20 versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 20 versus PIRMELLA 7 7 7.
AUROVELA FE 1/20 vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive